Hudson Bay Capital Management
MTNB icon

Hudson Bay Capital Management’s Matinas BioPharma MTNB Stock Holding History

Hudson Bay Capital Management’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12,000
Closed -$465K – 1049
2021
Q2 		$465K Buy
+12,000
New +$516K 0.01% 797
2020
Q3 		– Sell
-1,500
Closed -$57K – 607
2020
Q2 		$57K Buy
+1,500
New +$57.5K ﹤0.01% 472

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hudson Bay Capital Management's MTNB Position: Q3 2021 in Review

Hudson Bay Capital Management sold out of Matinas BioPharma (MTNB) in Q3 2021, closing a stake of 12,000 shares — an estimated $465K sold.

Hudson Bay Capital Management first reported a position in MTNB in Q2 2020 and held it in 2 quarters. The position peaked at $465K in Q2 2021. 67 funds tracked by Wall St. Rank hold MTNB as of Q3 2021.

  • Hudson Bay Capital Management reported no remaining Matinas BioPharma position as of Q3 2021 after selling out during the quarter.
  • Hudson Bay Capital Management sold 12,000 Matinas BioPharma shares in Q3 2021, an estimated $465K.
  • Hudson Bay Capital Management first reported a position in Matinas BioPharma in Q2 2020 and held it in 2 quarters.
  • Hudson Bay Capital Management's Matinas BioPharma position peaked at $465K in Q2 2021.
  • 67 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2021.

Based on Hudson Bay Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.